NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

524.40 -0.70 (-0.13%)

399.6K NSE+BSE Volume

NSE 10 Sep, 2025 12:29 PM (IST)

12,725.5

Market Cap

High in industry

1.1

Beta 1Year

High Volatility

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Search Inside the pdf :

Granules India Ltd.

22 Aug 2025

524.40

-0.13%

Modest Q1FY26 growth; facility ramp-up to drive recovery

Buy: Granules India Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.

Deven Choksey released a Buy report for Granules India Ltd. with a price target of 533.0 on 22 Aug, 2025.

Granules India Ltd.

06 Jun 2025

524.40

-0.13%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Validation activities have begun in Phase 2, Genome Valley, in this quarter. Also, the company continues to invest in research and development efforts aimed at building a pipeline of high-value molecules, with a focus on backward integration, especially in the oncology and CNS segment. The company has filed its first oncology molecule in this quarter....

Granules India Ltd. has gained 19.30% in the last 1 Month

Granules India Ltd.

28 May 2025

524.40

-0.13%

Broadly in-line quarter; margin resilience led by FDF

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.

Granules India Ltd. has an average target of 608.00 from 4 brokers.

Granules India Ltd.

17 Feb 2025

524.40

-0.13%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

25 Jan 2025

524.40

-0.13%

Finished dosages remain the key earnings driver

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered better-than-expected revenue, while EBITDA/PAT stood in line for the quarter. The traction in finished dosage (FDF) remained robust for six quarters now.

Granules India Ltd. has an average target of 608.00 from 4 brokers.

Granules India Ltd.

06 Nov 2024

524.40

-0.13%

Plants Resuming Operations and Upcoming Product Launches

Buy: Granules India Ltd.

Target

Sharekhan

Revenues stood at Rs. 957 crore, falling 19% y-o-y and 18% q-o-q, falling 5% short of our estimates.

Granules India Ltd. has gained 19.30% in the last 1 Month

Granules India Ltd.

12 Sep 2024

524.40

-0.13%

Gagillapur site under a cloud

Buy: Granules India Ltd.

Motilal Oswal

Granules India (GRAN) was issued a Form 483 with six observations for its Gagillapur site after a recent USFDA inspection.

Deven Choksey released a Buy report for Granules India Ltd. with a price target of 533.0 on 22 Aug, 2025.

Granules India Ltd.

16 Aug 2024

524.40

-0.13%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Granules India Ltd. has an average target of 608.00 from 4 brokers.

Granules India Ltd.

31 Jul 2024

524.40

-0.13%

FD and low base doubled earnings YoY

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) posted in-line revenue in 1QFY25. However, it delivered better-than-estimated 1QFY25 EBITDA/PAT led by the increased share of formulation sales.